Zobrazeno 1 - 10
of 842
pro vyhledávání: '"MARK M. JONES"'
Autor:
Jacques Delaunay, Grzegorz Mazur, Mark Minden, Agnieszka Wierzbowska, Mark M. Jones, Erhan Berrak, Hagop M. Kantarjian
Publikováno v:
Leukemia Research Reports, Vol 3, Iss 1, Pp 17-20 (2014)
Background: In a phase III trial, older patients with acute myeloid leukemia (N=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood
Externí odkaz:
https://doaj.org/article/b230e089f05f4e4e9049ab04802ea1d0
Autor:
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analy
Externí odkaz:
https://doaj.org/article/418f46ca455548afb6402a31a5392284
Autor:
Martin Griesshammer, Srdan Verstovsek, Julian Perez Ronco, Jingjin Li, Mahmudul Khan, Brian Gadbaw, Hui-Ling Zhen, Francesco Passamonti, Simon Durrant, Paola Guglielmelli, Jean-Jacques Kiladjian, Tamás Masszi, Güray Saydam, Mark M. Jones
Publikováno v:
Annals of Hematology. 97:617-627
WOS: 000426644800007
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
PubMed ID: 29396713
Ruxolitinib was well tolerated and superior to best available therapy (including interferon [IFN]) in controlling hematocrit without phlebotomy eligibility, normalizing blood counts, and improving po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dadda0e32b9a832b13abe6c63c87f13
https://doi.org/10.1007/s00277-017-3225-1
https://doi.org/10.1007/s00277-017-3225-1
Autor:
Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin
Publikováno v:
Ann Transl Med
Summary Background Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1–2 ECHO-202/KEYNOTE-037 study in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccb
https://www.zora.uzh.ch/id/eprint/172887/
https://www.zora.uzh.ch/id/eprint/172887/
Autor:
Scott J. Diede, Reinhard Dummer, Mark M. Jones, Caroline Robert, Lev V. Demidov, James Larkin, Omid Hamid, Tae Min Kim, Georgina V. Long, Jean-Jacques Grob, Tara C. Mitchell, Janet Maleski, Ana Arance, James R. Anderson, Christian Caglevic, Stéphane Dalle, Matteo S. Carlino, Thomas F. Gajewski
Publikováno v:
SSRN Electronic Journal.
Background: Immunotherapy combination treatments may improve patient outcomes. Epacadostat, an indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitor, and pembrolizumab, a programmed death protein (PD)-1 inhibitor, showed promising antitumour activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e3c7630dcd1422b6cc3a19bf4a24bb7
https://doi.org/10.2139/ssrn.3327362
https://doi.org/10.2139/ssrn.3327362
Autor:
Mari McQuitty, T Barbui, Prashanth Gopalakrishna, Francisco Cervantes, Viktoriya Stalbovskaya, Claire N. Harrison, Mark M. Jones, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Laurent Knoops, Heinz Gisslinger, Kang Sun
Publikováno v:
Leukemia
Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over placebo and best available therapy (BAT) in the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies. COMFORT-II was a rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6164884f9f9328d21083ade84d5fdde
http://europepmc.org/articles/PMC5399157
http://europepmc.org/articles/PMC5399157
Autor:
Paola Guglielmelli, Carole B. Miller, Mark M. Jones, Francesco Passamonti, Dany Habr, Simon Durrant, Fabrizio Pane, Pierre Zachee, Deborah S. Hunter, Mahmudul Khan, Srdan Verstovsek, William Sun, Jingjin Li, Jean-Jacques Kiladjian, Tamás Masszi, Martin Griesshammer, Claire N. Harrison
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d8c09071019779bb873a600db6ed2f1
http://hdl.handle.net/11588/721797
http://hdl.handle.net/11588/721797
Autor:
Bruno Martino, Hui-Ling Zhen, Francesco Passamonti, Pierre Zachee, Ruben A. Mesa, Deborah S. Hunter, Steffen Koschmieder, Ciro Roberto Rinaldi, Mark M. Jones, Yasmin Hasan, Abdulraheem Yacoub, Mamta Garg, Srdan Verstovsek, Alessandro M. Vannucchi, Dany Habr, Jennifer Byrne, Roger M. Lyons
Publikováno v:
British journal of haematology 176(1), 76-85 (2017). doi:10.1111/bjh.14382
British Journal of Haematology
British Journal of Haematology
British journal of haematology 176(1), 76-85 (2017). doi:10.1111/bjh.14382
Published by Wiley-Blackwell, Oxford [u.a.]
Published by Wiley-Blackwell, Oxford [u.a.]
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e854e8aa13c4eea6236c671d85278079
Autor:
Agnieszka Wierzbowska, Hagop M. Kantarjian, Grzegorz Mazur, Erhan Berrak, Jacques Delaunay, Mark M. Jones, Mark D. Minden
Publikováno v:
Leukemia Research Reports
Leukemia Research Reports, Vol 3, Iss 1, Pp 17-20 (2014)
Leukemia Research Reports, Vol 3, Iss 1, Pp 17-20 (2014)
Background: In a phase III trial, older patients with acute myeloid leukemia (N=485) received decitabine or treatment choice (supportive care or cytarabine). This post hoc analysis examined whether baseline renal and hepatic function and white blood
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84013880698a749c13408a09126abee1
Autor:
Carlos Besses, Alessandro M. Vannucchi, Fabrizio Pane, Vittorio Rosti, Simon Durrant, Francesco Passamonti, Igor Wolfgang Blau, Masayuki Hino, Carole B. Miller, Dany Habr, Mario Cazzola, Hui-Ling Zhen, Beatriz Moiraghi, Nathalie Francillard, Ruben A. Mesa, Srdan Verstovsek, Mark M. Jones, Jean-Jacques Kiladjian, Tamás Masszi, Pierre Zachee, Keita Kirito, Jingjin Li, Claire N. Harrison, Martin Griesshammer
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera. This preplanned analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b792086e9234ac9130beed0dede28da6
http://hdl.handle.net/11383/2046350
http://hdl.handle.net/11383/2046350